Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys.
about
HIV-1 prophylactic vaccines: state of the artHIV-Host Interactions: Implications for Vaccine DesignImmune correlates of vaccine protection against HIV-1 acquisitionA New Scientific Paradigm may be Needed to Finally Develop an HIV VaccineMechanisms of HIV protein degradation into epitopes: implications for vaccine designBiocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccinesHIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials.Progress in HIV-1 vaccine development.New concepts in HIV-1 vaccine developmentThe Number and Complexity of Pure and Recombinant HIV-1 Strains Observed within Incident Infections during the HIV and Malaria Cohort Study Conducted in Kericho, Kenya, from 2003 to 2006Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus VaccineSystems serology for evaluation of HIV vaccine trials.Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?Efficient generation of monoclonal antibodies from single rhesus macaque antibody secreting cells.HIV-1 vaccines: challenges and new perspectivesTherapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy.Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology.Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapyImmunologic strategies for HIV-1 remission and eradication.Epitope target structures of Fc-mediated effector function during HIV-1 acquisition.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesCharacterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimerChallenges in HIV Vaccine Research for Treatment and Prevention.First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.Novel vaccine vectors for HIV-1.Accelerating HIV-1 Vaccine Efficacy TrialsConstruction and evaluation of novel rhesus monkey adenovirus vaccine vectors.Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine developmentBalance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses.Evaluating potential T-cell epitope peptides for detecting HIV-specific T cell responses in a highly diverse HIV-1 epidemic from Cameroon.HIV vaccine research: the challenge and the way forwardHeterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.Can HIV Be Cured and Should We Try?
P2860
Q26740042-9DC303E5-982D-476C-B9D3-643090968FF9Q26765966-194CDB05-7EF6-4FE8-B7F7-EF6BA66C2726Q26778573-BEC3E653-16B2-4EA4-8B93-F7918449AE8EQ26830360-F7C93BD1-4AD9-49FF-BCA6-DDC05EB7A67BQ26866505-E8A350E9-8F0E-4792-8F75-F36CEA458718Q27333734-B16A12EC-8113-4AA9-A2E6-E2CBE138523BQ27687375-702FB697-FB9D-4A41-9BC5-6A51200994ABQ27693849-390217DC-EF4C-431D-B9D0-EE32CA6E2F53Q28067027-3BD042CE-028E-444F-B3FD-E1EE70F46DDCQ28608652-F1AA5E5C-F9B5-4EFF-BB8B-4D3D64D65878Q28822525-DAAA98C8-E1E9-45F9-8E34-F3B777575E19Q30238729-4EBB5445-3E01-4DDB-8191-DC66593019DFQ30362489-B6CA8CAC-769F-4E00-952F-78C87CB270D3Q30391848-5CEE7CEB-C2EE-446B-BE4F-EC50EAC2C104Q33577972-168C38DD-B4DC-4803-8C9D-0AF4558F8EC4Q33597744-E5FF8E1B-D971-43F4-956C-AD6495D9C927Q33601808-C41DEB13-EB05-4CEE-B71C-FE3C2018653BQ33611645-7E49F67F-5C4E-44C7-867E-DD1F93A040C7Q33804531-6A91BDCF-07EE-49F8-A0A7-6F0144266995Q33851717-EA8B657B-46E9-4AD0-98BE-4370E74340EBQ33865785-7F3E72E9-B9C2-4F2A-8949-0221396A228AQ33896523-14EB9934-EF94-4AEA-BD80-838209E67332Q33924272-F3F62C1A-8F18-46A2-88AA-E3FDE5FE0E64Q34057711-496DD29E-515A-4564-9575-2F30FE14B78CQ34059543-22FFE81F-F1DE-4491-BF01-CAFE34B14A30Q34148683-87F03CE4-88B8-49A1-8C96-14AA819DD981Q34209026-F9183072-B485-41DE-94A5-8D6EF9437661Q34230556-D6B07C4A-911B-4675-A216-DEFE3D9EDEB0Q34540352-A292D235-4423-40FF-8276-83176D59D96EQ34541191-31700C8C-91E4-4C93-B19F-C9D56C4A6AF7Q34580725-40A5A6A5-0524-402C-88EB-9CD3457B383AQ34991437-EF8AE2A2-1CF9-4AC6-A8A6-E3D35DC67CA4Q35072515-98418742-6059-4D09-ABEA-1F3457E1C643Q35156935-333110A6-4CDA-4D16-9F48-D4C475286CFAQ35212666-D026820D-0A92-496F-AB22-834C55EA53B3Q35218117-25F47A2F-C498-43D7-824B-D681E377EDC9Q35227007-5138E240-265C-41AD-A668-1B0738DFED57Q35344875-A08877E2-4F54-4C8B-9209-A14BFE94762FQ35569901-14F27A4B-6807-48D6-8C51-5E97B26C8C1EQ35690470-0AE6FB14-6464-4E0E-8365-9D3DA597A1DE
P2860
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Protective efficacy of a globa ...... challenges in rhesus monkeys.
@en
Protective efficacy of a globa ...... challenges in rhesus monkeys.
@nl
type
label
Protective efficacy of a globa ...... challenges in rhesus monkeys.
@en
Protective efficacy of a globa ...... challenges in rhesus monkeys.
@nl
prefLabel
Protective efficacy of a globa ...... challenges in rhesus monkeys.
@en
Protective efficacy of a globa ...... challenges in rhesus monkeys.
@nl
P2093
P2860
P50
P1433
P1476
Protective efficacy of a globa ...... challenges in rhesus monkeys.
@en
P2093
Anna G McNally
Anne-Sophie Dugast
Dan H Barouch
Elena E Giorgi
Erica N Borducchi
Erik A Billings
Galit Alter
Hanneke Schuitemaker
James J Szinger
Jinyan Liu
P2860
P304
P356
10.1016/J.CELL.2013.09.061
P407
P50
P577
2013-10-24T00:00:00Z